Patients’ whose treatment regimes’ require irradiated blood products are placed at risk of a potentially fatal complication known as Graft Versus Host Disease (GVHD) if they are transfused with blood products which are non-irradiated.

The following list outlines the key indications for requesting irradiated blood components when completing transfusion request cards.

- Hodgkin’s Lymphoma
- Bone Marrow Transplant (including stem cell harvesting in preparation for transplant)
- Treatment with purine analogue or similar chemotherapy used for haematological malignancy (e.g. fludarabine, cladribine, deoxycoformycin, bendamustine, clofarabine)
- Human Leucocyte Antigen (HLA) matched components
- All donations from first or second degree relatives
- Aplastic Anaemia patients receiving ATG immunosuppressive therapy
- Treatment with alemtuzumab (use includes for chronic lymphocytic leukaemia and solid organ transplants)
- All granulocyte (white cell) components
- All components for intra-uterine transfusion
- For children up to 6 months old who have received intrauterine transfusion before birth
- Congenital T lymphocyte immunodeficiency syndromes in childhood

For further information please refer to: CORP/PROT/011 Indications for Irradiated Blood Products

http://fcsharepoint/trustdocuments/Documents/CORP-PROT-011.doc